Cooley partner advises early IPO prep, highlights China’s impact on biotech

Rich Segal, a partner at Cooley LLP, emphasized the shifting dynamics of the biotech industry and the importance of early IPO preparation during an executive interview at Fierce Biotech Week.

Segal, who has spent over 15 years advising high-growth companies and institutional investors, pointed to China’s evolving role in biotech as a major trend. “We’re going to be seeing more assets developed in China,” Segal said. “That’s going to change how early-stage development looks, how the funding landscape looks.”

Despite concerns about geopolitical tensions, Segal sees opportunity in the changing landscape. “With change, there’s opportunity,” he said. “There’s going to be some cool new things that come out of this.”

Segal also stressed the need for companies to prepare for going public well before ringing the bell. “There’s no phase-in time,” he said. “You’ve got to have all your systems and processes and people in place.”

He advised companies to build in optionality and remain agile, noting that market windows can open and close quickly. “The companies that are most successful are the ones that are ready to execute and pivot,” Segal said.

For lean life sciences startups, Segal recommended leveraging outside advisors to fill internal gaps. “We’ve done IPOs with as few as five or six employees,” he said. “Let us be the G&A until it makes sense to build-out internally.”

His parting advice: raise capital when it’s available. “Raise more money than you think you’re going to need,” Segal said, citing the current government shutdown as a reminder of market unpredictability.

“Being a little too dilution-sensitive can leave companies vulnerable,” he added.

The editorial staff had no role in this post's creation.